Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TKNO Stock Summary
Top 10 Correlated ETFs
TKNO
In the News

Alpha Teknova, Inc. (TKNO) Q4 2022 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2022 Results Conference Call March 15, 2023 5:00 PM ET Company Participants Jen Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Joseph Flanagan - Cowen Matt Larew - William Blair Hannah Hefley - Stephens Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Teknova to Participate in Upcoming Investor Conferences
HOLLISTER, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conferences:

Alpha Teknova, Inc. (TKNO) Q3 2022 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2022 Earnings Conference Call November 21, 2022 4:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Teknova Third Quarter 2022 Financial Results Conference Call.

Teknova to Participate in Upcoming Investor Conferences
HOLLISTER, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conferences:

Teknova to Report Third Quarter 2022 Financial Results on November 9, 2022
HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, following the close of market.

Teknova to Participate in Upcoming Investor Conference
HOLLISTER, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conference.

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q2 2022 Results - Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Sara Michelmore - Head of Investor Relations, MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Stephanie Yan - Cowen Matt Larew - William Blair Jake Johnson - Stephens Operator Good day, and thank you for standing by. Welcome to the Teknova Second Quarter 2022 Financial Results Conference Call.

Teknova to Report Second Quarter 2022 Financial Results on August 10, 2022
HOLLISTER, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, following the close of market.

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q1 2022 Results - Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Sara Michelmore - Head of Investor Relations, MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Matthew Larew - William Blair Stephanie Yan - Cowen and Company Jacob Johnson - Stephens, Inc. Operator Good day, and thank you for standing by. Welcome to the Teknova First Quarter 2022 Financial Results Conference Call.
TKNO Financial details
TKNO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|
Revenue per share | 0.96 | 1.48 | 1.75 | |
Net income per share | -0.06 | 0.17 | -0.46 | |
Operating cash flow per share | 0.1 | 0.12 | -0.43 | |
Free cash flow per share | -0.02 | -0.14 | -1.37 | |
Cash per share | 0.46 | 0.24 | 0 | |
Book value per share | 2.31 | 2.48 | 0.01 | |
Tangible book value per share | 0.52 | 0.76 | 0.01 | |
Share holders equity per share | 2.31 | 2.48 | 0.01 | |
Interest debt per share | 0 | 0 | -0.03 | |
Market cap | 525.89M | 527.8M | 432.37M | |
Enterprise value | 521.79M | 524.48M | 432.3M | |
P/E ratio | -402.98 | 147.84 | -44.11 | |
Price to sales ratio | 26.17 | 16.86 | 11.72 | |
POCF ratio | 242.12 | 210.7 | -47.68 | |
PFCF ratio | -1.1K | -178.25 | -14.94 | |
P/B Ratio | 10.83 | 10.07 | 3.02K | |
PTB ratio | 10.83 | 10.07 | 3.02K | |
EV to sales | 25.97 | 16.76 | 11.72 | |
Enterprise value over EBITDA | -2.95K | 77.47 | -41.8 | |
EV to operating cash flow | 240.24 | 209.37 | -47.67 | |
EV to free cash flow | -1.09K | -177.13 | -14.93 | |
Earnings yield | 0 | 0.01 | -0.02 | |
Free cash flow yield | 0 | -0.01 | -0.07 | |
Debt to equity | 0.21 | 0.2 | 0.16 | |
Debt to assets | 0.17 | 0.17 | 0.14 | |
Net debt to EBITDA | 23.16 | -0.49 | 0.01 | |
Current ratio | 2.76 | 4.14 | 13.07 | |
Interest coverage | 0 | 0 | 20.39 | |
Income quality | -1.66 | 0.7 | 0.93 | |
Dividend Yield | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.38 | 0.26 | 0.55 | |
Research and developement to revenue | 0.04 | 0.05 | 0.12 | |
Intangibles to total assets | 0.64 | 0.58 | 0.21 | |
Capex to operating cash flow | -1.22 | -2.18 | 2.19 | |
Capex to revenue | -0.13 | -0.17 | -0.54 | |
Capex to depreciation | -1.63 | -2.67 | -6.89 | |
Stock based compensation to revenue | 0 | 0.01 | 0.04 | |
Graham number | 1.79 | 3.07 | 0.27 | |
ROIC | -0.03 | 0.06 | 864.67 | |
Return on tangible assets | -0.06 | 0.13 | -74.72 | |
Graham Net | 0.15 | 0.06 | 0 | |
Working capital | 9.84M | 12.45M | 93.46K | |
Tangible asset value | 10.94M | 15.94M | 107.89K | |
Net current asset value | 5.45M | 5.91M | 77.9K | |
Invested capital | 0 | 0 | 0.08 | |
Average receivables | 0 | 4.78M | 3.29M | |
Average payables | 0 | 1.2M | 818.62K | |
Average inventory | 0 | 3.07M | 1.79M | |
Days sales outstanding | 54.24 | 76.61 | 0.05 | |
Days payables outstanding | 24.33 | 44.07 | 0.04 | |
Days of inventory on hand | 81.3 | 96.55 | 0.1 | |
Receivables turnover | 6.73 | 4.76 | 7.91K | |
Payables turnover | 15 | 8.28 | 8.57K | |
Inventory turnover | 4.49 | 3.78 | 3.57K | |
ROE | -0.03 | 0.07 | -68.46 | |
Capex per share | -0.13 | -0.26 | -0.94 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.34 | 0.36 | 0.4 | 0.42 | 0.38 | |
Net income per share | -0.12 | -0.13 | -0.2 | -0.22 | -0.8 | |
Operating cash flow per share | -0.17 | -0.11 | -0.19 | -0.21 | -0.3 | |
Free cash flow per share | -0.31 | -0.37 | -0.4 | -0.6 | -0.53 | |
Cash per share | 3.5 | 3.12 | 2.73 | 2.31 | 1.77 | |
Book value per share | 5.22 | 5.11 | 4.94 | 4.76 | 3.99 | |
Tangible book value per share | 3.95 | 3.85 | 3.69 | 3.52 | 3.35 | |
Share holders equity per share | 5.22 | 5.11 | 4.94 | 4.76 | 3.99 | |
Interest debt per share | 0.42 | 0.42 | 1.14 | 1.3 | 1.28 | |
Market cap | 697.22M | 573.68M | 387.11M | 235.69M | 93.82M | |
Enterprise value | 611.03M | 498.04M | 342.6M | 207.37M | 79.93M | |
P/E ratio | -53.62 | -39.33 | -17.61 | -9.5 | -1.04 | |
Price to sales ratio | 74.24 | 56.74 | 34.73 | 20.16 | 8.77 | |
POCF ratio | -144.14 | -186.14 | -74.43 | -40.37 | -11.26 | |
PFCF ratio | -79.74 | -54.67 | -34.82 | -14.06 | -6.29 | |
P/B Ratio | 4.77 | 4.01 | 2.79 | 1.77 | 0.84 | |
PTB ratio | 4.77 | 4.01 | 2.79 | 1.77 | 0.84 | |
EV to sales | 65.06 | 49.26 | 30.74 | 17.74 | 7.48 | |
Enterprise value over EBITDA | -179.98 | -121.65 | -66.94 | -35.89 | -3.62 | |
EV to operating cash flow | -126.32 | -161.6 | -65.87 | -35.52 | -9.59 | |
EV to free cash flow | -69.88 | -47.46 | -30.82 | -12.37 | -5.36 | |
Earnings yield | 0 | -0.01 | -0.01 | -0.03 | -0.24 | |
Free cash flow yield | -0.01 | -0.02 | -0.03 | -0.07 | -0.16 | |
Debt to equity | 0.16 | 0.16 | 0.33 | 0.37 | 0.43 | |
Debt to assets | 0.14 | 0.14 | 0.25 | 0.27 | 0.3 | |
Net debt to EBITDA | 25.39 | 18.48 | 8.7 | 4.9 | 0.63 | |
Current ratio | 17.9 | 13.07 | 7.28 | 6.77 | 5.68 | |
Interest coverage | 0 | 132.42 | 449.46 | -236.64 | -327.91 | |
Income quality | 1.49 | 0.85 | 0.95 | 0.94 | 0.37 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.6 | 0.67 | 0.65 | 0.6 | 0.61 | |
Research and developement to revenue | 0.15 | 0.14 | 0.18 | 0.17 | 0.18 | |
Intangibles to total assets | 0.21 | 0.21 | 0.19 | 0.19 | 0.11 | |
Capex to operating cash flow | 0.81 | 2.4 | 1.14 | 1.87 | 0.79 | |
Capex to revenue | -0.42 | -0.73 | -0.53 | -0.93 | -0.62 | |
Capex to depreciation | -5.22 | -9.47 | -7.88 | -13.79 | -9.03 | |
Stock based compensation to revenue | 0.05 | 0.06 | 0.07 | 0.08 | 0.09 | |
Graham number | 3.69 | 3.87 | 4.67 | 4.86 | 8.47 | |
ROIC | 0.1 | 0.33 | -0.19 | -0.12 | -0.4 | |
Return on tangible assets | -0.02 | -0.03 | -0.04 | -0.04 | -0.16 | |
Graham Net | 2.91 | 2.51 | 1.41 | 0.87 | 0.41 | |
Working capital | 104.88M | 93.46M | 79.3M | 68.41M | 57.74M | |
Tangible asset value | 110.62M | 107.89M | 103.52M | 98.72M | 94.15M | |
Net current asset value | 88.14M | 77.9M | 46.4M | 31.54M | 21.79M | |
Invested capital | 0.08 | 0.08 | 0.23 | 0.27 | 0.32 | |
Average receivables | 5.72M | 5.21M | 5.92M | 6.55M | 6.15M | |
Average payables | 2.98M | 2.78M | 2.64M | 2.22M | 2.45M | |
Average inventory | 4.14M | 4.9M | 5.91M | 7.17M | 9.12M | |
Days sales outstanding | 55.09 | 41.54 | 57.86 | 45.63 | 53.6 | |
Days payables outstanding | 58.27 | 39.43 | 47 | 19.85 | 52.96 | |
Days of inventory on hand | 77.26 | 94.61 | 99.75 | 110.48 | 156.88 | |
Receivables turnover | 1.63 | 2.17 | 1.56 | 1.97 | 1.68 | |
Payables turnover | 1.54 | 2.28 | 1.91 | 4.53 | 1.7 | |
Inventory turnover | 1.16 | 0.95 | 0.9 | 0.81 | 0.57 | |
ROE | -0.02 | -0.03 | -0.04 | -0.05 | -0.2 | |
Capex per share | -0.14 | -0.26 | -0.21 | -0.39 | -0.23 |
TKNO Frequently Asked Questions
What is Alpha Teknova, Inc. stock symbol ?
Alpha Teknova, Inc. is a US stock , located in Hollister of Ca and trading under the symbol TKNO
What is Alpha Teknova, Inc. stock quote today ?
Alpha Teknova, Inc. stock price is $3.26 today.
Is Alpha Teknova, Inc. stock public?
Yes, Alpha Teknova, Inc. is a publicly traded company.